Brind.
  1. Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.

Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.

4 reports, 2 independent Updated Fri 00:00
No new developments lately
Reports
4
Developments
3
Repetition
25%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.

Who's involved

What this event is mainly about
NovartisAvidity

How it developed

Newest first. Tap a step to see who reported it.
  1. The $12B acquisition of Avidity assets by Novartis triggers calls for board shake-up.1 source
  2. Novartis continues development of medicines related to Avidity.1 source
  3. Novartis successfully acquired Avidity in a $12 billion deal.1 source

Keep exploring

Part of

Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story